Tests BCG bladder cancer treatment given at home with support tools
Tests home delivery of BCG bladder treatment for adults with bladder cancer.
Plain-language title generated from the registry record
Registry title: Intravesical Treatment of Bladder Cancer at Home, Multi-modal Treatment Support
Key facts
- Where
- Philadelphia, United StatesSee the site
Where in United States
- Abramson Cancer CenterPhiladelphia, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Abramson Cancer Center at Penn Medicine
- Trial code
- NCT07048496
- Record updated
- 5 October 2026
- Original description
The proposed project will have two separate cohorts. The first will be to perform a more in-depth qualitative assessment of the barriers and facilitators for treatment compliance for non-muscle invasive bladder cancer. The second arm will be to create and test a BCG at home program. Participants in the second cohort will be enrolled in a conversational agent to measure patient symptoms and quality of life and improve self-efficacy.Read full original descriptionShow less
Intravesical Treatment of Bladder Cancer at Home, Multi-modal Treatment Support
The proposed project will have two separate cohorts. The first will be to perform a more in-depth qualitative assessment of the barriers and facilitators for treatment compliance for non-muscle invasive bladder cancer. The second arm will be to create and test a BCG at home program. Participants in the second cohort will be enrolled in a conversational agent to measure patient symptoms and quality of life and improve self-efficacy.
Inclusion: Age 18 years or older; completed intravesical treatment for non-muscle invasive bladder cancer within the past year Cohort 1 inclusion criteria for key stakeholders; Age 18 years or older; experience with the delivery of BCG delivery for more than 2 years; Cohort 2 inclusion criteria; Age 18 years or older; diagnosed with non-muscle invasive bladder cancer and prescribed BCG for initial therapy.
Exclusion: inability to receive BCG therapy (i.e. - previous reaction with BCG); inability to undergo catheterization (i.e. - history of urethral stricture); Cohort 1 exclusion criteria; inability to provide informed consent; Cohort 2 exclusion criteria; inability to provide informed consent; no access to mobile phone; inability to respond to written conversations in English.